Exciting research and development is going on throughout the world and as it’s not possible to create all new products internally, UCB actively monitors developments in these areas and pursues ...

UCB now has three core brands: Cimzia, for Crohn's disease and rheumatoid arthritis (RA), epilepsy treatment Vimpat and Neupro for Parkinson's disease. These three products are sustaining the firm ...

A UCB drug with a novel approach to plaque psoriasis won a long-awaited FDA approval, positioning it to bring patients a new choice in a crowded market of products for the prevalent skin condition.

These key products helped offset the impact of Zyrtec and Keppra's patent losses, and the company has continued to shape its expertise in immunology and central nervous system disorders.

When it comes to breaking into an increasingly saturated market of psoriasis treatments, Blair said UCB is hoping the campaign can underscore the efficacy of Bimzelx compared to other products. By ...

The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or ...

Both products are approved only for use in adults. UCB markets an FDA-approved FcRn blocker called Rystiggo, a once weekly infusion that addresses both AChR and MuSK antibodies. The Belgian ...

These key products helped offset the impact of Zyrtec and Keppra's patent losses, and the company has continued to shape its expertise in immunology and central nervous system disorders.

UCB said in a statement there would be no impact ... "The demand for central nervous system products in China has been increasing over the past decade," CBC CEO Fu Wei said.